ESR1 and breast carcinoma: In addition, ROC analysis for 5-year relapse-free survival on ER+ tamoxifen-treatment breast cancer patients showed an AUC of 0.61 (95% CI: 0.54–0.68; p-value = 0.004) (Figure 4D).